Nonsyndromic mitral valve prolapse (MVP) is a common degenerative cardiac valvulopathy of unknown etiology that predisposes to mitral regurgitation, heart failure and sudden death 1 . Previous family and pathophysiological studies suggest a complex pattern of inheritance 2-5 . We performed a meta-analysis of 2 genome-wide association studies in 1,412 MVP cases and 2,439 controls. We identified 6 loci, which we replicated in 1,422 cases and 6,779 controls, and provide functional evidence for candidate genes. We highlight LMCD1 (LIM and cysteine-rich domains 1), which encodes a transcription factor 6 and for which morpholino knockdown of the ortholog in zebrafish resulted in atrioventricular valve regurgitation. A similar zebrafish phenotype was obtained with knockdown of the ortholog of TNS1, which encodes tensin 1, a focal adhesion protein involved in cytoskeleton organization. We also showed expression of tensin 1 during valve morphogenesis and describe enlarged posterior mitral leaflets in Tns1 −/− mice. This study identifies the first risk loci for MVP and suggests new mechanisms involved in mitral valve regurgitation, the most common indication for mitral valve repair 7 .
The prevalence of nonsyndromic MVP has been estimated as 2.4% in the general population 8 . Familial aggregation 9, 10 , presence in rare connective-tissue syndromes 11 and the identification of four linked loci 2-5 indicate genetic heterogeneity for MVP. Additional factors, such as age-and sex-dependent penetrance, with a possible association with myocardial structural and functional abnormalities, suggest additional genetic complexity 12 . To identify susceptibility loci for MVP, we conducted an initial discovery meta-analysis on 2 independent French genome-wide association studies (GWAS) that included 1,412 MVP cases and 2,439 controls (Supplementary Table 1) , all of European ancestry, for ~4.8 million genotyped or imputed common (minor allele frequency (MAF) > 0.1) SNPs ( Fig. 1 and Supplementary Fig. 1 ). Three loci showed genome-wide significant associations with MVP (P < 5 × 10 −8 ) ( Table 1 ). The strongest association (rs12465515: odds ratio (OR) = 1.33, P = 1.08 × 10 −8 ) was observed at 2q35 in a ~424-kb gene desert region where the nearest upstream genes are TNP1, IGFBP5 and IGFBP2 and the nearest downstream genes are DIRC3 and TNS1 ( Table 1) . The two other genome-wide significant loci were at 17p13 (lead SNP rs216205: OR = 1.35, P = 3.02 × 10 −8 ) in an intron of SMG6 and at 22q12 near MN1 and PITPNB (rs11705555: OR = 1.34, P = 4.47 × 10 −8 ) ( Table 1) . We followed up 23 loci with suggestive evidence of association (P < 1 × 10 −5 ) in a first replication panel that included US and Spanish cases and controls of European ancestry (set 1 and set 2, respectively; Supplementary Fig. 1) .
We genotyped or imputed a total of 47 SNPs (23 loci). An intermediate meta-analysis including the discovery set and follow-up sets 1 and 2 (n cases = 2,312 and n controls = 8,296) identified a subset of 24 SNPs (15 loci) with significant associations with MVP (P < 0.01), which were genotyped or imputed in 2 additional case-control studies from Canada and France (sets 3 and 4, respectively; Supplementary  Fig. 1 ). In the global meta-analysis that included 2,864 cases and 9,218 controls, 3 additional loci associated with MVP at the genomic level ( Table 1 and Supplementary Table 2 ). The overall strongest association was observed at 3p13 for rs171408, which maps in an intron of LMCD1 (OR = 1.32, P = 1.29 × 10 −11 ; Table 1) . Two additional signals were identified, one at 21q22 near CBR1 and SETD4 (rs62229266: OR = 1.22, P = 1.18 × 10 −8 ) and the other at 14q24 near SIPA1L1 and PCNX (rs17767392: OR = 1.23, P = 2.27 × 10 −8 ; Table 1 ). We also confirmed the three genome-wide significant signals identified in Genetic association analyses highlight biological pathways underlying mitral valve prolapse the discovery samples with lead SNPs rs12465515 near IGFBP5 and TNS1 (OR = 1.25, P = 3.11 × 10 −11 ), rs11705555 near PITPNB and MN1 (OR = 1.23, P = 1.39 × 10 −8 ) and rs216205 in SMG6 (OR = 1.24, P = 1.46 × 10 −8 ). Overall, we observed consistency in the direction of effect as well as nominally significant association in the follow-up meta-analysis and did not detect significant heterogeneity (P > 0.05) among the case-control studies ( Table 1) .
Many individuals in the general population with MVP show few clinical symptoms, if any 1 . Nonetheless, a substantial subset of these individuals are at risk of heart failure and cardiac-related death, and MVP is the most common cause of isolated mitral regurgitation requiring surgical repair 7 . To investigate whether the confirmed MVP risk alleles are more prevalent among more severely affected individuals who require valve repair or replacement, we analyzed 1,680 French MVP cases who underwent surgical intervention and compared them to 3,259 French controls (Supplementary Table 3) . We did not find a stronger effect for any of the MVP risk alleles, except for a slight increase in the frequency of the risk-associated allele of rs11705555 at the PITPNB-MN1 locus (OR = 1.31, 95% confidence interval (CI) = 1.19-1.44, P = 1.88 × 10 −8 ). Overall, our findings support the idea that MVP is under significant genetic control with susceptibility loci of relatively homogeneous effect sizes (OR from 1.22 to 1.33).
The MVP-associated loci implicate four intergenic (IGFBP5-TNS1, SETD4-CBR1, PITBNB-MN1 and PCNX-SIPA1L1) and two intronic (LMCD1 and SMG6) regions (Supplementary Table 4) . From an initial list of 53 genes (located within 500 kb to 1 Mb of the lead SNP) we identified candidate genes at each locus on the basis of proximity to the sentinel SNP, expression level in the heart, presence of expression quantitative trait locus (eQTL) signal in the publically available Gene-Tissue Expression (GTEx) database, proximity to previously identified GWAS signals for cardiovascular traits and a biological link with mitral valve or general cardiac development (see Supplementary  Table 5 and the Supplementary Note for full details on the gene prioritization strategy for each locus).
We then investigated the expression patterns of candidate genes during valve development in mouse embryos by immunohistochemistry (IHC) at three time points that represented (i) completion of the endothelial-to-mesenchymal transition (EMT; embryonic day (E) 13.5), (ii) valve sculpting and elongation (E17.5) and (iii) achievement of the mature adult form (at 9 months). Functional antibodies were only available for Tns1 and Igfbp5 (encoded at 2q35 in humans) and Pitpnb (encoded at 22q12 in humans). We also prioritized candidate genes in the MVP risk loci using morpholino-based knockdown of the clear zebrafish orthologs of the human genes, which, after filtering (Supplementary Note), limited our analysis to eight genes at the three human loci: igfbp2a, igfbp2b, igfbp5a, igfbp5b and tns1 at the 2q35 locus; lmcd1 at the 3p13 locus; and smg6 and sgsm2 at the 17p13 locus.
At 2q35, rs12465515 lies within a large intergenic region, and TNS1 and IGFBP5 were identified as the best two candidate genes (Supplementary Table 4 ). TNS1 maps 750 kb downstream of the association signal at the 2q35 locus (Fig. 2) . Tensin 1 protein localizes to focal adhesions and interacts with actin (as does filamin A), and variants can cause a rare X-linked form of MVP 13 . Tensin 1 interacts with the cytoplasmic tails of integrins to anchor stress fibers and has an important role in determining the metastatic capacities of cancer cells 14 . IGFBP5, which encodes insulin-like growth factor-binding protein 5 (IGFBP5), is known to modulate muscle differentiation and mediate high glucose-induced profibrotic effects in cardiac fibroblasts 15 . IGFBP5 has also been demonstrated to modulate the migration and adhesion of cancer cells 15 and could potentially be at play in valve development and valvular interstitial cell integrity.
We observed only faint nonspecific staining for Igfbp5 in the valves of developing and adult mice (Supplementary Fig. 2 ). In contrast, mouse IHC data showed sustained expression of tensin 1 during valve morphogenesis, with expression stronger along the atrial aspect of the forming leaflet (Fig. 3a) . We also found that tensin 1 expression was maintained during adulthood and was localized to endothelial and valvular interstitial cells (Fig. 3a) . Hematoxylin and eosin (H&E) histological staining in 9-month-old Tns1 −/− mice showed enlarged posterior mitral leaflets as compared to those in wild-type littermates (Fig. 3b) . In addition, valves from a Tns1 −/− mouse showed evidence of myxomatous degeneration, as indicated by increased proteoglycan content and loss of normal matrix stratification, demonstrated by the accumulation of proteoglycan in the valves (Fig. 3c) . Preliminary echographic exploration of Tns1 −/− mice (n = 2) showed slight leaflet displacement (0.4 mm) as compared to the leaflets in wild-type mice (0.1 mm), consistent with larger leaflets but no mitral regurgitation ( Supplementary Fig. 3 ) and indicating subtle anomalies of the mitral valve that warrant future confirmation.
In zebrafish experiments ( Fig. 2b-e) , a significant increase in the incidence of atrioventricular (AV) regurgitation was observed in tns1 knockdown animals as compared to control animals for both morpholinos (3-fold (P = 0.02) and 1.1-fold (P = 0.01) increases; Supplementary Videos 1 and 2) but not in animals with simultaneous knockdown of the igfbp2 and igfbp5 isoforms (Fig. 2b) . In situ hybridization identified high tns1 expression throughout the developing heart, and knockdown of this gene diminished the aggregation of endothelial cells at the developing valve ( Fig. 2c and Supplementary  Fig. 4) . Furthermore, although notch1b expression remained localized Expected -log 10 (P value)
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PITPNB-MN1 SMG6 a b l e t t e r s npg l e t t e r s to the developing valve, the distribution of the valve development marker bmp4 was highly disorganized ( Fig. 2d and Supplementary Fig. 5 ).
Together, these results support TNS1 as the best candidate at the 2q35 locus for contributing to MVP pathogenesis. The association signal at 3p13 is intronic to LMCD1 (Fig. 4a) . LMCD1, also called dyxin, is a member of the LIM-domain family of zinc-finger proteins that act as co-regulators of transcription. Lmcd1 in mouse is highly expressed in cardiac tissue and has been shown to be a direct repressor of Gata6 (encoding GATA-binding protein 6), an important regulator of cardiac development 6 . Somatic mutations in LMCD1 were described as potential oncogenic events in hepatocellular carcinoma metastasis because of their promotion of cell migration 16 . Knockdown of lmcd1 in zebrafish resulted in significantly increased AV regurgitation with two different morpholinos (4.7-fold (P = 0.001) and 1.2-fold (P = 0.009) increases in AV regurgitation; Fig. 4b-d and Supplementary  Video 3) . In addition, morphological analysis of the developing myocardium indicated that lmcd1 morphants had a moderate reduction in cardiac looping (Supplementary Video 3) . Although lmcd1 is expressed throughout the heart, after lmcd1 knockdown, we observed no abnormalities in the expression patterns of the valve development markers notch1b and bmp4 (Supplementary Fig. 5 ) and no mislocalization of endothelial cell aggregation ( Supplementary  Fig. 4) . Further investigation will be required to determine whether the AV regurgitation phenotype observed in embryos with lmcd1 knockdown is due to a primary valve defect or a more general defect in cardiac development. Previous in vitro and in vivo studies in mice showed that Lmcd1 (dyxin) augments calcineurin activity 17 . Calcineurin signaling is required for AV endocardium EMT and subsequent valve morphogenesis in zebrafish 18 . rs355134, a variant highly correlated with the top SNP, rs171408 (r 2 = 0.84 according to 1000 Genomes Project data), is located in a predicted binding site for myocyte enhancer factor 2A (MEF2A), a key transcription factor in cardiac development 19 . We have previously shown that Mef2c regulates matrix production in mouse valves 20 . Our data extend the role of LMCD1 to valve development, and the putative implication of LMCD1 in the matrix production that is regulated by MEF2A deserves future investigation.
Among the remaining MVP-associated loci, we detected expression of Pitpnb, the ortholog of a candidate gene at 22q12 in humans, in valve endothelial and interstitial cells within the mouse mitral leaflets at each of the time points investigated ( Supplementary  Fig. 6 ). At the locus in zebrafish orthologous to 17p13, knockdown of neither smg6 nor sgsm2 npg l e t t e r s led to an abnormal valvular phenotype (Supplementary Fig. 7) . Additional candidate genes need to be explored at 17p13, which has been associated with aortic root size 21 and coronary heart disease 19 .
Despite the widespread prevalence of MVP, its molecular basis has largely been elusive. The first molecular pathways implicated in MVP were described on the basis of observations of disease in individuals with Marfan or Ehlers-Danlos syndrome, findings that highlighted the importance of extracellular matrix composition 22 , the transforming growth factor (TGF)-β growth factor pathway 12, 23 and valve cell proliferation and differentiation 24 . Several mechanisms describing structural changes as a basis for MVP have also been proposed, including enlargement and flattening of the mitral annulus 25 that can impose additional stresses on genetically susceptible valves and chordae 26 . In this first GWAS of nonsyndromic MVP, we have identified several susceptibility loci that support the concept that genetic variants affecting the expression of proteins during valve development can progressively affect mitral valve function into adult life, as was recently shown for filamin A 27 . In particular, we provide genetic and functional evidence that TNS1 and LMCD1, both implicated in cell proliferation and migration, contribute to mitral valve degeneration, 
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Leducq Transatlantic MITRAL Network. The majority of patients were recruited as a major project of the Leducq MITRAL Network, a transatlantic consortium with basic-science and clinical investigators from 10 clinical and research centers investigating the physiopathology of mitral valve disease. Six centers recruited MVP cases: MVP-Nantes and MVP-France for the initial GWAS effort; MVP-USA, the Framingham Heart Study (FHS) and Prolapso Mitral en Centros Españoles (PROMESA) at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) for initial replication; and HEGPSurgical Cases with QCCMRC data sets for the last replication stage. Cases were compared with controls (FHS, PROMESA-CNIC and QCCMRC) or the general population (D.E.S.I.R. for the initial GWAS and one replication stage, SU.VI.MAX for the GWAS) (Supplementary Fig. 1). Case recruitment criteria. Our consensus inclusion criteria included adult patients (≥18 years of age) with idiopathic MVP if they presented displacement into the left atrium of any part of the mitral valve leaflet(s) ≥2 mm beyond a line connecting the annular hinge points on the parasternal long-axis view of the left ventricle by two-dimensional echocardiography 28, 29 . We also included patients who had undergone previous surgeries for pure severe mitral regurgitation due to MVP, supported by an operative report and written confirmation of the diagnosis by the surgeon (MVP-France, MVP-Nantes and Surgery Cases). All cases were validated by a local, experienced team of cardiologists on the basis of clinical and echocardiography records. Recruitments excluded patients with MVP associated with other heart disease (coronary artery disease with papillary muscle disruption, hypertrophic cardiomyopathy or rheumatic disease) or known syndromes (such as Marfan and Ehlers-Danlos). Local ethics committees approved all studies, and all patients and controls provided written informed consent. Recruitment procedures for DNA collection are detailed for each cohort in the Supplementary Note.
GWAS genotyping and quality control. Genotyping of the discovery cohorts was performed independently on different genetic platforms that included standard quality control measures of genotyping and data acquisition from diverse high-density genotyping arrays (Supplementary Table 1 ). We excluded participants with genotype call rates <97% and individual heterozygosity levels <10,000 (determined as the outlier limit after visual inspection). We excluded SNPs that had a MAF <0.1, had a call rate <95%, were monomorphic or had an exact Hardy-Weinberg equilibrium P value of <0.0001 in controls and <1 × 10 −7 in demographically homogenous cases to exclude SNPs that showed very large deviations.
Imputation. To complement the directly genotyped SNPs, we performed large-scale imputation in the four discovery cohorts. First, genotyped SNPs in cases and controls were phased using the SHAPE-IT (v1) program 30 . Then, the imputation of 4.8 million common SNPs (MAF > 0.1 in 1000 Genomes Project Europeans, proper-info > 0.4) was carried out using IMPUTE (v2) 31 in ~7-Mb chunks. The reference panel used was the Phase I integrated variant set release (v3) in NCBI Build 37 (hg19). We used similar procedures to impute non-genotyped SNPs in the FHS replication cohort with MACH software (0.3 r2_hat) 32 .
Direct genotyping in the replication sets. MGH cases from follow-up set 1 and all cases and controls from set 2 were genotyped at the Massachusetts General Hospital PNGU Core Lab using the Sequenom iPLEX Gold application and MassARRAY system. Follow-up sets 3 and 4 were genotyped at the LGC genomics company using KASP genotyping chemistry. We excluded samples for nine individuals that failed genotyping for all SNPs and had SNPs with call rates <0.90. No SNP deviated from Hardy-Weinberg equilibrium (P > 0.05).
Demographic analyses. The ancestry of the participants was assessed using a multidimensional scaling technique implemented in PLINK 33 . SNPs were selected for short-range linkage disequilibrium (LD) independence (r 2 > 0.2). The multidimensional scaling method was applied to the identity-by-state matrix, and we excluded outliers on the first two components ( Supplementary  Fig. 8 ) using an expectation maximization-fitted Gaussian mixture clustering method implemented in the R package M-CLUST, assuming one cluster and noise (Supplementary Note).
Genome-wide and replication association with MVP status. We applied a logistic regression (additive) model as implemented in SNPTEST 31 to test the association with MVP in the GWAS discovery set with the first five principal components included as covariates. We also used SNPTEST and/or logistic regression on allele dosage in replication sets when cases and/or controls were imputed for genotypes (FHS in set 1 and D.E.S.I.R. 2 in set 4; Supplementary  Fig. 1 ). Genetic relatedness was also taken into account when appropriate (FHS cohort). For directly genotyped case-control studies (sets 2 and 3), we used logistic regression as implemented in PLINK.
For the GWAS meta-analysis, we applied the inverse normal strategy 34 . Because the number of controls greatly exceeded the number of cases in all studies, we used the effective sample size as advised in METAL software 35 : w = 4/(1/n cases + 1/n controls ).
Regional association plots for 2q35, 3p13 and 17p13 were created using LocusZoom 36 .
Protein detection in mouse embryos and adult hearts. Standard histological and IHC procedures were used, as previously described 27 . For all immunohistochemistry experiments, 5-min antigen retrieval was performed with VectaStain in a pressure cooker (Cuisinart). The antibodies used for immunological experiments were to tensin 1 (Novus, NB100-41087) and myosin heavy chain (Developmental Hybridoma Banks, MF20). Primary antibodies were used for IHC at a 1:100 dilution; Hoechst 33342 (nuclear stain) was used at a 1:10,000 dilution. Appropriate secondary antibodies were used for detection.
Histology and expression studies were performed in adult (9-month-old) wild-type (Tns1 +/+ ) and knockout (Tns1 −/− ) mouse hearts. For histology, adult (9-month-old) hearts were processed for H&E staining and IHC, as previously described 37 . For all analyses, male mice were used (n = 3 for each genotype; deemed sufficient as studies were a qualitative assessment of expression patterns and did not involve quantifiable metrics). The antibodies used for IHC were to hyaluronan-binding protein (HABP) to stain proteoglycans (1:100 dilution; EMD Millipore, 385911) and collagen I (1:100 dilution; MDbio, 203002); Hoechst was used to stain nuclei (1:10,000 dilution; Invitrogen). All mouse experiments were performed under protocols approved by the Institutional Animal Care and Use Committee at the Medical University of South Carolina. Prior to cardiac resection, mice were sacrificed in accordance with the Guide for the Care and Use of Laboratory Animals.
Zebrafish experiments.
Zebrafish experiments were performed in accordance with approved Institutional Animal Care and Use Committee (IACUC) protocols. TuAB zebrafish strains were reared according to standard techniques. Minimal effective doses of antisense morpholino oligonucleotides were injected at the single-cell stage, and morpholino-injected animals were compared to controls injected with nontargeting morpholino. The oligonucleotide sequences are provided in Supplementary Table 6 . Embryos were scored for the presence of AV regurgitation at 72 h.p.f. using high-speed videography. Semiquantitative PCR was used to demonstrate the efficacy of morpholino knockdown (Supplementary Fig. 9 ). In situ hybridizations for tissue-specific expression of lmcd1, tns1, bmp4 and notch1b were performed as described 38 . To visualize the localization of the developing cardiac cushions, flk-EGFP reporter fish were microinjected with morpholinos to tns1 or lmcd1. After manual excision of the heart at 72 h.p.f., the hearts were counterstained with rhodamine-labeled phalloidin and mounted using Vectashield. Confocal micrographs were acquired on a Zeiss 510 LSM microscope with a 20× air lens. Final images represent two-dimensional projections of a z series (ImageJ). 
